David Michael Simon

US Patent:

6569866, May 27, 2003

Filed:

Aug 6, 2001

Appl. No.:

09/922873

Inventors:

David Lew Simon - Mansfield Center CT 06250

International Classification:

A61K 3144

US Classification:

514282, 514281, 514410, 424449

Abstract:

A nalmefene transdermal delivery system useful for the treatment of human patients suffering from opioid addiction.

US Patent:

20030035827, Feb 20, 2003

Filed:

Aug 13, 2001

Appl. No.:

09/928854

Inventors:

David Simon - Mansfield Center CT, US

International Classification:

A61K009/70

US Classification:

424/449000

Abstract:

Compositions are described for linking drugs or pharmaceutical agents to substrates such that the drug or pharmaceutical agent can be rendered relatively ineffective when not exposed to an enabling enzyme contained within a compartment of a living animal or human.

US Patent:

20030199439, Oct 23, 2003

Filed:

Apr 22, 2002

Appl. No.:

10/127359

Inventors:

David Simon - Mansfield Center CT, US

International Classification:

A61K038/33
A61K031/7052
A61K031/485
A61K031/445
A61K031/192

US Classification:

514/012000, 514/282000, 514/317000, 514/023000, 514/161000, 514/570000

Abstract:

A pharmaceutical composition comprising an opioid agonist analgesic and an 34 nicotinic receptor antagonist effective to separate the brain-derived wanting of the opioid from the analgesic or anti-diarrhea effect of the opioid agonist.

US Patent:

20030199496, Oct 23, 2003

Filed:

Jul 1, 2002

Appl. No.:

10/186402

Inventors:

David Simon - Mansfield CT, US

International Classification:

A61K031/5513
A61K031/353

US Classification:

514/221000, 514/454000

Abstract:

A pharmaceutical composition comprising an 34 nicotinic receptor antagonist effective to diminish the brain-derived feeling of pleasure due to increased dopamine in the pleasure-reward center of the brain typically associated with administration of an opioid agonist analgesic, a muscle relaxant, an anti-seizure medication, an anxiolytic drug, an amphetamine, a central nervous system stimulant, a tetrahydrocannabinol or that associated with an otherwise pleasurable or self-reinforcing behavior.

US Patent:

20030211157, Nov 13, 2003

Filed:

Nov 27, 2002

Appl. No.:

10/306657

Inventors:

David Simon - Mansfield Center CT, US

International Classification:

A61K031/573
A61K031/485
A61K009/14

US Classification:

424/486000, 514/282000, 514/179000

Abstract:

The present invention relates to novel methods and compositions for administration of water-soluble small molecules for the treatment of opioid addiction, alcoholism and HIV infection, especially where the water-soluble small molecules are pentacyclic and structurally similar to nalmefene, buprenorphine, 6-beta-naltrexol and nalbuphine.

US Patent:

20040024006, Feb 5, 2004

Filed:

Jul 25, 2003

Appl. No.:

10/628089

Inventors:

David Simon - Mansfield Center CT, US

International Classification:

A61K031/485

US Classification:

514/282000

Abstract:

The invention is directed in part to dosage forms comprising a combination of an analgesically effective amount of an opioid agonist analgesic and a neutral receptor binding agent or a partial mu-opioid agonist, the neutral receptor binding agent or partial mu-opioid agonist being included in a ratio to the opioid agonist analgesic to provide a combination product which is analgesically effective when the combination is administered as prescribed, but which is less analgesically effective or less rewarding when administered in excess of prescription. Preferably, the combination product affects an opioid dependent individual differently from an opioid naïve individual, and has a diminished likelihood of being associated with a life-threatening adverse drug reaction, especially in the opioid dependent individual.

US Patent:

20050026842, Feb 3, 2005

Filed:

May 8, 2004

Appl. No.:

10/841408

Inventors:

David Simon - Mansfield CT, US

International Classification:

A61K038/08
A61K031/485

US Classification:

514016000, 514017000, 514282000

Abstract:

Methods for use of pharmaceutical compositions containing an opioid agonist analgesic and an α3β4 nicotinic receptor antagonist effective to separate the brain-derived wanting of the opioid from the analgesic or anti-diarrhea effect of the opioid agonist.

US Patent:

20060235038, Oct 19, 2006

Filed:

Apr 4, 2006

Appl. No.:

11/397439

Inventors:

David Simon - Mansfield Center CT, US

International Classification:

A61K 31/485

US Classification:

514282000

Abstract:

The present invention relates to novel compositions, methods and therapeutic uses for nalmefene, a unique opioid antagonist drug. The invention teaches administering nalmefene by means that function to produce optimal steady-state plasma or serum concentrations. These means plus functions are claimed for treating alcoholism and pathological gambling.